Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

90.83 -0.52 (-0.57%)
Streaming Delayed Price Updated: 11:41 AM EST, Dec 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
74 75 Next >
News headline image
AstraZeneca Highlights Significant Gains Across Three Major Cancer Trials At ASCO ↗
AstraZeneca reports major survival benefits in breast and gastric cancer trials with Enhertu, Imfinzi, and camizestrant at ASCO 2025. 
Via Benzinga
News headline image
How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma ↗
Three new cancer drugs could help make a dent in the company's ambitious plans for 2030. 
Via Investor's Business Daily
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial
From AstraZeneca
Via Business Wire
News headline image
IMFINZI® (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
From AstraZeneca
Via Business Wire
News headline image
Looking Into AstraZeneca's Recent Short Interest ↗
 
Via Benzinga
News headline image
Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
From AstraZeneca
Via Business Wire
News headline image
Why Tempus AI Stock Plummeted This Week ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Why Artificial Intelligence Stock Tempus AI Is Tumbling Today ↗
An investment management firm known for short-selling the stocks it speaks against is now targeting a high-risk, high-reward stock purchased by a high-profile politician. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
The Promise of Quantum Computing ↗
The race to quantum supremacy is on. While this future will not come tomorrow, big tech companies are building to the technology's "ChatGPT moment." 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
AstraZeneca’s record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer
From AstraZeneca
Via Business Wire
News headline image
3 Promising Growth Stocks You Can Buy for Less Than $100 ↗
Via The Motley Fool
News headline image
How Does D-Wave Stack Up Against Quantum Competitors?
D-Wave, IonQ, and Rigetti are three of the most talked-about quantum computing firms; how do these three companies stack up against one another? 
Via MarketBeat
News headline image
Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma
From AstraZeneca
Via Business Wire
News headline image
George Soros Loads Up On First Solar Calls: What Does He Know That Wall Street Doesn't? ↗
Soros Fund Management, in a surprise move, revealed a bold new bet on First Solar Inc., scooping up 1.6 million call options. 
Via Benzinga
News headline image
Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price ↗
Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition. 
Via Investor's Business Daily
News headline image
Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda ↗
Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors. 
Via Benzinga
News headline image
P/E Ratio Insights for AstraZeneca ↗
 
Via Benzinga
News headline image
AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025
From AstraZeneca
Via Business Wire
News headline image
Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say ↗
JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting... 
Via Stocktwits
Topics ETFs Government Stocks
News headline image
AstraZeneca Reports Positive Data From Cancer Drug Trial: Retail Sentiment Brightens ↗
The company noted that no new safety concerns were identified with the combination of Imfinzi and BCG induction and maintenance therapy in the trial. 
Via Stocktwits
News headline image
IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial
From AstraZeneca
Via Business Wire
News headline image
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks ↗
Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential. 
Via Benzinga
Topics ETFs Government
News headline image
Tempus AI Stock: Time to Double Down or Cut and Run?
Tempus AI is gaining traction and on track for profits this year; high short interest and rising institutional activity point to significant upside potential. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11
From AstraZeneca
Via Business Wire
News headline image
Tempus AI Strikes $200M Deal With AstraZeneca, Pathos To Build World's Largest Oncology Model ↗
The biggest strategic highlight for Tempus AI Inc. (NASDAQ: TEM) during the first quarter was a multi-million dollar deal to build "the world's largest foundation model for oncology." 
Via Benzinga
Topics Artificial Intelligence
News headline image
AstraZeneca Gets Approval For Oncology Drug To Treat Mantle Cell Lymphoma In EU: But Retail Sentiment Dips ↗
The approval is based on positive results from a phase 3 trial, which demonstrated that Calquence plus bendamustine and rituximab reduced the risk of disease progression or death by 27% compared to... 
Via Stocktwits
News headline image
AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma ↗
AstraZeneca's Breztri met primary goals in four asthma trials, including KALOS, LOGOS, LITHOS, and VATHOS, involving over 5,000 patients. 
Via Benzinga
News headline image
Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time. ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
AstraZeneca’s Breztri Therapy Meets Primary Goals In Late-Stage Trials To Treat Asthma: Retail’s Positive ↗
AstraZeneca said on Friday that the full results from the two trials will be shared with regulatory authorities and presented at an upcoming medical meeting. 
Via Stocktwits
News headline image
BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma
From AstraZeneca
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.